These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 20425432)

  • 1. Management of myelodysplastic syndromes in the geriatric patient.
    Ritchie EK; Lachs MS
    Curr Hematol Malig Rep; 2009 Jan; 4(1):3-9. PubMed ID: 20425432
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Managing myelodysplastic symptoms in elderly patients.
    Ria R; Moschetta M; Reale A; Mangialardi G; Castrovilli A; Vacca A; Dammacco F
    Clin Interv Aging; 2009; 4():413-23. PubMed ID: 19966910
    [TBL] [Abstract][Full Text] [Related]  

  • 3. British Society for Haematology guidelines for the management of adult myelodysplastic syndromes.
    Killick SB; Ingram W; Culligan D; Enright H; Kell J; Payne EM; Krishnamurthy P; Kulasekararaj A; Raghavan M; Stanworth SJ; Green S; Mufti G; Quek L; Cargo C; Jones GL; Mills J; Sternberg A; Wiseman DH; Bowen D
    Br J Haematol; 2021 Jul; 194(2):267-281. PubMed ID: 34180045
    [No Abstract]   [Full Text] [Related]  

  • 4. How I treat patients with myelodysplastic syndromes.
    Stone RM
    Blood; 2009 Jun; 113(25):6296-303. PubMed ID: 19383969
    [No Abstract]   [Full Text] [Related]  

  • 5. Strategies for achieving transfusion independence in myelodysplastic syndromes.
    Thomas ML
    Eur J Oncol Nurs; 2007 Apr; 11(2):151-8. PubMed ID: 16935559
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Diagnosis and Treatment of Myelodysplastic Syndromes: A Review.
    Sekeres MA; Taylor J
    JAMA; 2022 Sep; 328(9):872-880. PubMed ID: 36066514
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The costs of drugs used to treat myelodysplastic syndromes following National Comprehensive Cancer Network Guidelines.
    Greenberg PL; Cosler LE; Ferro SA; Lyman GH
    J Natl Compr Canc Netw; 2008 Oct; 6(9):942-53. PubMed ID: 18926103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myelodysplastic syndrome: An update on diagnosis and therapy.
    Koppel A; Schiller G
    Curr Hematol Malig Rep; 2009 Jan; 4(1):10-6. PubMed ID: 20425433
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk-based management of myelodysplastic syndrome.
    Steensma DP; Tefferi A
    Oncology (Williston Park); 2007 Jan; 21(1):43-54; discussion 57-8, 62. PubMed ID: 17313156
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
    Nimer SD
    J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Novel therapies in low- and high-risk myelodysplastic syndrome.
    Germing U; Schroeder T; Kaivers J; Kündgen A; Kobbe G; Gattermann N
    Expert Rev Hematol; 2019 Oct; 12(10):893-908. PubMed ID: 31353975
    [No Abstract]   [Full Text] [Related]  

  • 12. Management of myelodysplastic syndromes: 2008 update.
    Scott BL; Estey E
    Oncology (Williston Park); 2008 Nov; 22(12):1344-52. PubMed ID: 19086598
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New Approaches to Myelodysplastic Syndrome Treatment.
    Bazinet A; Bravo GM
    Curr Treat Options Oncol; 2022 May; 23(5):668-687. PubMed ID: 35320468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Hypomethylating agents and other novel strategies in myelodysplastic syndromes.
    Garcia-Manero G; Fenaux P
    J Clin Oncol; 2011 Feb; 29(5):516-23. PubMed ID: 21220589
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Myelodysplastic syndromes: 2015 Update on diagnosis, risk-stratification and management.
    Garcia-Manero G
    Am J Hematol; 2015 Sep; 90(9):831-41. PubMed ID: 26294090
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent advances in low- and intermediate-1-risk myelodysplastic syndrome: developing a consensus for optimal therapy.
    Stone R; Sekeres M; Garcia-Manero G; Lyons RM
    Clin Adv Hematol Oncol; 2008 Dec; 6(12):1-15. PubMed ID: 19385003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Selection of patients with myelodysplastic syndromes from a large electronic medical records database and a study of the use of disease-modifying therapy in the United States.
    Ma X; Steensma DP; Scott BL; Kiselev P; Sugrue MM; Swern AS
    BMJ Open; 2018 Jul; 8(7):e019955. PubMed ID: 30037860
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Treatment of MDS].
    Usuki K
    Rinsho Ketsueki; 2014 Oct; 55(10):1882-92. PubMed ID: 25297752
    [No Abstract]   [Full Text] [Related]  

  • 19. Update on the pharmacotherapy for myelodysplastic syndromes.
    Duong VH; Komrokji RS; List AF
    Expert Opin Pharmacother; 2014 Sep; 15(13):1811-25. PubMed ID: 25080144
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How to manage lower-risk myelodysplastic syndromes.
    Sekeres MA
    Leukemia; 2012 Mar; 26(3):390-4. PubMed ID: 21904382
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.